Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First...

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract...

Chronic Lower Back Pain Treatment Market Size to Surpass USD 4.52 Billion by 2030, exhibiting a CAGR of 9.5% Pune, India, July 31, 2023 (GLOBE NEWSWIRE) -- The chronic lower back pain treatment market size was valued at USD 2.21 billion in 2022 and is projected to reach a valuation of USD 2.40 billion in...

Chronic Lower Back Pain Treatment Market Size [2022-2028] | Industry Share, Growth, Trends, Revenue, Competitive Landscape, Forecast Report Pune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The rising prevalence of chronic pain across the world is expected to drive the global chronic lower back pain treatment market. As per the National...

Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Persica Pharmaceuticals has completed the first stage of its clinical trial on unique injectable PP353, to treat chronic lower back pain Novel approach applicable to 20% of all CLBP populationsFirst...